Institute of Health Economics
[If you want to visit this web site Click
Above]
Use Ctrl-F to
search this page for a keyword.
You must provide
your e-mail before you can download the FREE reports available at
this site.
STATISTICS AVAILABLE:
-
Drug Cost List
Provides a list of costs for specifics drugs by province. EXCEL
format.
-
2001 working
papers
- 01-02:Strategic Orientation and
Benchmarking in the Canadian Pharmaceutical and Biotechnology
Industries
-
2000 working papers
- 00-17: Treatment Variations of
Femoral Neck Fractures in Alberta
- 00-16: Economic Evaluation of
the Study of Cardiovascular Risk Intervention by Pharmacists
(SCRIP)
- 00-15: A Technology Index of
Hospital Expenditure Growth in Canada
- 00-14: Health Expenditures and
Technology in the Treatment Heart Attacks
- 00-13: A Pilot Study Assessing
the Impact of Community Pharmacists Care on the Clinical and
Humanistic Outcomes of People with Type 2 Diabetes
- 00-12: A Policy Impact Analysis
of Pharmaceutical Cost Containment Strategies in Alberta
- 00-11: Development of a
Disease-Specific Health-Related Quality of Life Instrument for
People with Cystic Fibrosis
- 00-10: Functional Dependence
Following Hip Fracture
- 00-09: The Public Purchase of
Private Surgical Services: A Systematic Review of the Evidence
on
- 00-08: An Empirical Review of
Health Expenditures and Technology
- 00-07: Technologies Used for
Managing and Preventing Acute Myocardial Infarction
- 00-06: An Economic Evaluation
of Home Care as an Alternative to Institutionalization
- 00-05: Health Technology
Assessment in Canada: A Ten Year Review, Part 2
- 00-04: Health Technology
Assessment in Canada: A Ten Year Review, Part 1
- 00-03: Cost Effectiveness
Analysis and the Societal Approach: Should the Twain Ever
Meet?
- 00-02: Public Policies Related
to Drug Formularies in Canada: Economic Issues
- 00-01: A Rapid Structured
Review of Studies on Health-Related Quality of Life and
Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia
-
1999 working papers
- 99-10: Methods of Educating the
Public and Pharmacists on Prescribing, Monitoring and Use of
Drugs
- 99-09: Risk Selection and
Matching in Performance-Based Contracting
- 99-08: Health-Related Quality
of Life for Adult and Pediatric Cystic Fibrosis Patients: A
Regression Approach to Assessing the Impact of Recombinant
Human rhDNase
- 99-07: (An Overview) Canadian
Administrative Data: Quality and Assessment
- 99-06: Paying For Physician
Services In Canada: The Institutional, Historical and Policy
Contexts - Part 1 of Incentive Effects of Physician
Remuneration Schemes
- 99-05: Models for Funding
Prescription Drug Programs
- 99-04: Systematic Review of
Pharmacy Reimbursement Literature
- 99-03: A Systematic Review of
Quinolone, Cephalosporin, and Macrolide Use in Ambulatory Care
- 99-02: Cost of Care for
Individuals With Cystic Fibrosis in Alberta: A Regression
Approach to Determining Important Cost Drivers
- 99-01: The Roles of Health
Economics in Canadian Drug Firms
-
1998 working papers
- 98-12: The Classification and
Measurement of Private Health-Related Costs: Application to
HIV/AIDS
- 98-11: Measuring and Predicting
ICU Cost Per Patient Day: a Literature Review
- 98-10: Cost Effectiveness of
Streetworks Needle Exchange Program of Edmonton, Alberta
- 98-09: Determinants and
Consequences of Technological Change in Health Care: Acute
Myocardial Infarction (AMI) in Alberta, Canada
- 98-08: Burden of Illness of
Employees on U.S. Employers
- 98-07: Wages, Alcohol Use, and
Smoking: Simultaneous Estimates
- 98-06: Comparison of the EQ-5D
and SF-12 in a General Population Survey in Alberta, Canada
- 98-05: A Cost-Utility Analysis
of Pacemakers for the Treatment of Neurally Mediated Syncope
- 98-04: Nedocromil Sodium as
Single Dose Prophylactic Treatment of Exercise-Induced
Bronchoconstriction in Asthma: A Meta-Analysis
- 98-03: National Pharmacare,
Reference-Based Pricing, and Drug R & D:A Critique of The
National Forum on Health's Recommendations For Pharmaceutical
Policy
- 98-02: Alberta-Based SF-12
Summary Scores
- 98-01: Measuring Quality of
Life in Pediatric Patients
FEATURES:
|
